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PURPOBE: To assess the impact of the use of 
mupirocin ointment on colonization, transmis- 
sion, and infection with methicillin-resistant 
Staphyl~us mreus (MRSA) in a long-term- 
care facility. 
PATIENTS AND MlWHOm AU 321 residents of a 
Veterans Affairs long-term-care facility from 
June 1990 through June 1991 were studied for 
MRSA colonization and infection. MRSA-colo- 
nized patients received mupirocin ointment to 
nares in the first 7 months and to nares and 
wounds in the second 5 months. The effect of 
mupirocin use on MRSA colonization and infec- 
tion was monitorxxL All S. aureus strains isolated 
were tested for the development of resistance to 
mupirocin 
RESULT& A total of 65 patients colonized with 
MRSA received mupirocin ointment. Mupirocin 
rapidly eliminated MRSA at the sites treated in 
most patients by the end of 1 week Weekly 
maintenance mupirocin was not adequate to 
prevent recurrences-40% of patients had re- 
currence of MRSA. Overall, MRSA colonization 
in the facility, which was 22.7% f 1% prior to 
the use of mupirocin, did not change when mu- 
pirocin was used in nares only (222% f 2.1%), 
but did decrease to 11.5% f 1.8% when mupiro- 
tin was used in nares and wounds. Although col- 
oniration decreased, roommate-to-roommate 
transmission and MRSA infection rates, low to 
begin with, did not change when mupirocin was 
WXXL Mupirocin-r&&ant MESA strains were 
isolated in 10.8% of patients. 
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CONCLUSIONS: Mupirocin ointment is effective 
at decreasing colonization with MESA. How- 
ever, constant surveillance was required to iden- 
tify patients colonized at admission or experi- 
encing recurrence of MRSA during 
maintenance treatment. Long-term use of mu- 
pirocin selected for mupirocin-resistant MESA 
strains. Mupirocin should be saved for use in 
outbreak situations, and not used over the long 
term in facilities with endemic MRSA 
colonization. 
C olonization and infection with methicillin-re- sistant Staphylococcus aureus (MRSA) have 
become major concerns over the last decade in both 
acute- and chronic-care settings [l-9]. While some 
studies have documented that long-term-care facil- 
ities serve as a reservoir for MRSA and contribute 
to the spread of the organism when patients are 
transferred to acute-care hospitals 141, other studies 
have shown the important role that hospitalized 
patients colonized with MRSA play in bringing 
MRSA into long-term-care facilities [7]. To date, 
the role of long-term-care facilities in the perpetua- 
tion and spread of MRSA has not been completely 
elucidated [8,9]. 
Attempts to eradicate colonization with MRSA 
are frequently initiated in patients in acute-care 
hospitals and long-term-care facilities. One method 
that has been used is application of mupirocin oint- 
ment to the anterior nares. Mupirocin has excellent 
antistaphylococcal activity and has been shown to 
be effective in treating staphylococcal skin infec- 
tions [lo]. Eradication of staphylococci from the 
anterior nares with mupirocin has been shown for 
both health care workers and patients who are colo- 
nized with MRSA [ll-141. However, whether the 
use of mupirocin will decrease colonization and ulti- 
mately infections with MRSA in patients in the 
long-term-care setting is not known. Whether the 
use of mupirocin is without risks, including the 
development of resistance, also has not been 
established. 
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We previously assessed the importance of MRSA 
in our long-term-care facility. Over the course of 1 
year, we determined the prevalence and incidence 
of colonization, patterns of acquisition, and risk of 
infection with MRSA [7]. We undertook the current 
study to assess the effect of the use of mupirocin on 
colonization, transmission, and infection with 
MRSA in this facility and to determine whether 
long-term maintenance therapy with mupirocin 
was associated with the development of resistance 
to the drug. 
PATIENTS AND METHODS 
Facility and Patients 
The Ann Arbor Veterans Affairs Nursing Home 
Care Unit is a 120-bed long-term-care facility at- 
tached to the 300-bed acute-care hospital. Patients 
are cared for by three services-geriatric evalua- 
tion, rehabilitation, and long-term care-but these 
three services are not physically separated. 
Study Design 
During the initial year (June 1989 to June 1990) 
of this several-year study, baseline data regarding 
MRSA colonization and infection were obtained on 
all patients in the facility. The results have been 
published previously [7]. During the second year of 
the study (June 1, 1990, to June 1, 1991), all pa- 
tients colonized with MRSA were treated with mu- 
pirocin ointment in an attempt to decrease MRSA 
colonization and to determine whether this had an 
effect on infection rates. 
Initial surveillance cultures were performed on 
all patients in the facility when the second year 
began (June 1990). Over the course of the next year, 
all patients had cultures on admission to the facili- 
ty, monthly as long as they remained in the facility, 
and whenever they returned to the facility after 
transfer to the acute-care hospital. After MRSA- 
positive patients were entered into the mupirocin 
study, they had surveillance cultures performed 
weekly until the study ended on June 1, 1991. 
From mid-June 1990 to the end of December 
1990, patients colonized with MRSA in their anteri- 
or nares were treated with nasal application of mu- 
pirocin; wounds were not treated. From January 1, 
1991, to June 1, 1991, mupirocin was used in both 
anterior nares and wounds. 
Definition of Colonization/Infection 
Patients were considered colonized with MRSA 
when one or more cultures from any site yielded 
MRSA on one or more occasions [7]. MRSA infec- 
tions were defined by the criteria set forth by the 
Centers for Disease Control [15]. 
Drug Regimen 
All patients who had cultures from anterior nares 
or wounds positive for MRSA were asked to partici- 
pate in the study. The study protocol had been ap- 
proved by the Human Studies Subcommittee and 
the Research and Development Committee of the 
Ann Arbor Veterans Affairs Medical Center, and all 
patients gave written consent. 
Topical mupirocin 2% ointment in a polyethylene 
glycol base was applied as a thin film to anterior 
nares and the base of the wound by the nursing staff 
using a sterile swab. Mupirocin was applied to 
wounds at the same time each day in conjunction 
with a routine dressing change. Wounds were cov- 
ered with fine-mesh gauze and gauze bandages, not 
with occlusive dressings. Anterior nares were treat- 
ed daily for 1 week; wounds were treated daily for 2 
weeks. After this, both sites were treated on Mon- 
day, Wednesday, and Friday for 3 weeks, and then 
on Wednesday thereafter. All patients were treated 
for a minimum of 3 months after all cultures were 
negative for MRSA before treatment was stopped. 
Weekly surveillance cultures were performed every 
Tuesday. 
If patients remained colonized on the first follow- 
up culture (done on a day off therapy in Week 2 for 
nares and Week 3 for wounds), daily mupirocin 
treatment was continued until they were culture- 
negative; then the regimen outlined above was em- 
ployed. When relapses with one or two colonies oc- 
curred, no change was made in the treatment 
regimen. If more than two colonies were isolated, 
daily treatment was again initiated for 2 weeks fol- 
lowed by once-weekly treatment after this. 
Patients were asked whether they had side effects 
from application of mupirocin (burning, itching, 
congestion, pain); signs of irritation (rhinorrhea, er- 
ythema) were also assessed. 
Microbiologic Methods 
The following sites were assessed for MRSA colo- 
nization: anterior nares, perineum, rectum, and 
wounds. These areas were swabbed with sterile ra- 
yon-tipped applicator sticks, which were then 
placed immediately into Stuart transport media 
and within 2 hours streaked onto colistin nalidixic 
acid agar containing 5% sheep’s blood. After incu- 
bation at 35OC for 24 hours, yellow or white colonies 
were selected. Cat&se-positive, Accu-Staph (Carr- 
Scarborough, Decatur, GA)-positive organisms 
were identified as 5’. aureus. Organisms that grew 
after 24 hours at 35OC on Mueller-H&on agar 
plates containing 6 rg/mL oxacillin and 4% sodium 
chloride were confirmed as MRSA; methicillin-sen- 
sitive S. aureus (MSSA) showed no growth on oxa- 
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cillin plates [16]. All isolates were phage-typed by 
standard methods at the Michigan Department of 
Public Health Laboratory [17]. 
tients are not included in the analysis of the efficacy 
of mupirocin. 
Mupirocin resistance was determined initially by 
a screening method utilizing growth on Mueller- 
Hinton agar containing 2 rg/mL mupirocin. The 
minimal inhibitory concentration (MIC) of mupiro- 
tin for each isolate was confirmed using a microtiter 
method described previously [18]. High-level resis- 
tance was defined as an MIC greater than 100 
Bg/mL, low-level resistance as an MIC between 4 
rg/mL and 100 rg/mL, and sensitive as less than or 
equal to 2 rg/mL. 
Thus, a group of 65 patients (20.2% of the 321 
patients in the overall study) were treated with mu- 
pirocin and followed to assess the effects of treat- 
ment on MRSA colonization; 3 of the 65 patients 
were treated on 2 separate occasions either 1 month 
(2 patients) or 2 months (1 patient) apart. The 
mean age of the patients treated was 64.2 f 1.5 
years; there were 63 men and 2 women. The mean 
time they were treated with mupirocin was 3.4 f 0.3 
months; the mean time patients were followed with 
weekly cultures was 4.6 f 0.5 months. 
On three separate occasions (June 1990, January 
1991, and June 1991), the environment was sampled 
for MRSA using Rodac plates (Becton Dickinson, 
Lincoln Park, NJ) containing mannitol salt agar 
(Difco, Detroit, MI) as described previously [7]. Ev- 
ery occupied room was sampled at the following 
sites: floor beside the patient’s bed, bed rail, bed- 
side table, bathroom floor, and sink. Common areas 
(nursing stations, television rooms, recreation 
rooms) were also sampled. Sampling was performed 
prior to the use of mupirocin, after the first 7 
months when anterior nares alone had been treated, 
and after the next 5 months when anterior nares 
and wounds had been treated. Phage typing was 
done on all isolates. No changes had occurred in 
housekeeping routines over the course of the year in 
which the environmental samples were taken. 
Of the 65 patients, 48 were entered into the study 
during the first 7 months and received mupirocin to 
anterior nares only. In the next 5 months, there 
were 17 new patients entered into the study. In 
addition, eight patients who had entered during the 
first 7 months continued in the study and two pa- 
tients were treated for a second time when they were 
readmitted to the facility during the second 5 months. 
No patient experienced local irritation from the 
application of mupirocin ointment, no signs of local 
irritation were noted, and no patient left the study 
because of intolerance to the drug. 
Eradication of MRSA Colonization in 
Individual Patients 
Statistics 
Results are expressed as mean f SE. The x2 test 
or one-way analysis of variance was used to compare 
colonization rates. 
RESULTS 
Mupirocin quickly eliminated MRSA from the 
anterior nares. In the first 6 months, 40 of 48 pa- 
tients (83.3%) had cleared their nares of MRSA by 
the end of 1 week of treatment, and 45 of 48 (93.7%) 
had clearance by the end of Week 3. In the second 5 
months, when both nares and wounds were treated, 
MRSA was eliminated more rapidly from the nares; 
18 of 19 (94.7%) patients had clearance in 1 week 
and all had clearance by Week 3 (Figure 1). 
Overall, 321 patients were followed from June 
1, 1990, to June 1, 1991. Admission and monthly 
surveillance cultures were obtained on these pa- 
tients, and MRSA colonization and infection 
rates were determined. The mean age of the pa- 
tients was 65.2 & 0.6 years; 315 were men and 6 
were women. 
Mupirocin Treatment 
Eighty-nine of the 321 patients (27.7%) were 
found to be colonized with MRSA and were asked to 
participate in the mupirocin treatment trial. Of 
these 89 patients, only 2 refused either mupirocin 
treatment or weekly surveillance cultures and re- 
mained in the facility; 12 others were transferred, 
discharged, or died prior to beginning therapy with 
mupirocin, and 10 received less than 2 weeks of 
therapy prior to discharge or death. These 24 pa- 
In the first 7 months, wound MRSA colonization 
data were available from monthly surveillance cul- 
tures only. Treatment of anterior nares alone had 
minimal effects on MRSA colonization of wounds. 
Of 19 patients whose wounds were colonized with 
MRSA, 13 had persistent or intermittent coloniza- 
tion of these wounds even though the nares had 
been cleared of MRSA. In the second 5 months, 
wound MRSA colonization data were available on a 
weekly basis and showed that MRSA was cleared 
rapidly from wounds. Fourteen of 17 patients who 
began mupirocin in the second 5 months had 
wounds colonized with MRSA. In all but 2 of these 
14 patients (14.3%), MRSA was eliminated from 
their wounds after 1 week of therapy; 1 patient, who 
had an ischemic ulcer, remained positive after 2 
weeks of therapy. Fifty percent of patients whose 
wounds were treated had ischemic ulcers, 23% had 
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Figure 1. Eradication of MRSA in anterior nares in patients 
treated with mupirocin ointment applied only to anterior na- 
res (open circles wlth broken line) or to both anterior nares 
and wounds (colld circles wlth solid Ilne). 
TABLE I 
Colonization With Methicillin-Resistant S. amus (MRSA) at Various 





Sites Nares Only Nares/Wounds 
Samoled (6/8%/90) (6/90-12/90) (l/91-6/91) due 
Nares 15.2 + 1.0 1z.y f ;:; 6.3 2 0.8 0.0001 
Perineum 3.7 + 0.8 1.2 2 0.4 0.260 
Rectum 4.6 k 0.9 5:3 I 0 6 1.4 f 0.5 0.032 
Wounds+ 40.1 * 4.4 35.6 f 2:6 22.9 + 5.0 0.057 
1 
lata are expressed as the mean percent of patients ? SE colonized with MRSA each month at the 
es indicated. Data analyzed by one-way analysis of variance. 
xpressed as the percent of patients who had wounds that were colonized with MRSA. 
decubitus ulcers, 18% had abdominal or thoracic 
postoperative wounds, and 9% had tracheostomies. 
Recurrence of MRSA in Patients Receiving Mupirocin 
Recurrence of MRSA colonization in treated pa- 
tients was not uncommon. During the first 7 
months, 18 of 48 (37.5%) patients had at least 1 
recurrence of MRSA in the anterior nares. In the 
second 5 months, 8 of 17 (47.1%) patients admitted 
into the study in the second 5 months and 1 of 10 
(10%) patients carried over from the first 7 months 
had a recurrence, overall rate = 9 of 27 (33.3%). 
Although most patients [14] had only one discrete 
episode of recurrence, eight patients had two, three 
patients had three, and one patient each had four 
and five recurrences. In 23 of 27 patients, recur- 
rences were in nares, and in 4 patients recurrences 












Figure 2. Percent of patients colonized with MSSA (whlte 
bars) or MRSA (black bars) each month. The mean coloniza- 
tion rate for MRSA in the 12 months preceding use of mupiro- 
tin is shown as a broken line labeled “PRE-MUP % MRSA.” 
The time point at which mupirocin use was initiated for ante- 
rior nares only is indicated by the arrow labeled “Nares.” The 
time point at which mupirocin was initiated for use in both 
anterior nares and wounds is indicated by the arrow labeled 
“Nares/Wounds.” There was a significant difference in MRSA 
colonization when premupirocin use was compared with na- 
res-only use and nares/wounds use, p = 0.0001, by one-way 
analysis of variance. 
those patients with MRSA colonization of wounds 
in the last 5 months of the study. 
Of 48 separate episodes of recurrence, 46 of the 
MRSA strains were phage-typed; 20 (43.5%) were a 
new phage group and presumably represented re- 
colonization with a different organism; 26 (56.5%) 
were the same phage group and most likely repre- 
sented relapse with the original colonizing strain. 
All but 11 of these 48 episodes required an increase 
in the frequency of mupirocin administration to 
clear the organism. All recurrences but 2 occurred 
when the patient was receiving weekly maintenance 
mupirocin treatment. 
MRSA Colonization in the Facility 
Prior to the use of mupirocin (June 1, 1989, to 
June 1, 1990), the mean monthly colonization rate 
for MRSA in all residents of the facility was 22.7% f 
1.0%. This did not change during the 7 months mu- 
pirocin was used only in anterior nares (22.2% f 
2.1%), but decreased significantly when both nares 
and wounds were treated (11.5% f 1.8%), p = 0.0001 
(Figure 2). By the last 2 months of the study, the 
MRSA colonization rate had fallen to 7.3%. 
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Flgure 3. Persistence of MRSA ex- 
pressed as mean number of pa- 
tients colonized each month with 
MRSA (& SE), comparing the 6 
months in which mupirocin was 
used in anterior nares only (Nares) 
with the 6 months in which mupiro- 
tin was used in both anterior nares 
and wounds (Nares/Wounds). Pre- 
viously positive (+) patients are 
those who were colonized with 
MRSA prior to mupirocin use in the 
facility and those who had a recur- 
rence despite mupirocin use; (+) 
on admission are patients who 
came into the facility with MRSA; 
new converters are patients who 
acquired MRSA in the facility. Data 
analyzed by one-way analysis of 
variance. 
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The overall rate of colonization with MSSA de- 
creased slightly, comparing premupirocin colonixa- 
tion rates (19.8% f 1.2%) with the first 7 months 
(19.5% f 1.4% colonized) and the next 5 months of 
mupirocin use (15.6% f 0.9% colonized), but these 
differences were not significant, p = 0.113. Again, as 
with MRSA, the lowest MSSA colonization rate was 
noted in the last 2 months of the study. 
Colonization rates at various sites for the year 
prior to mupirocin use, the 7 months when nares 
alone were treated, and the 5 months when nares 
and wounds were treated are shown in Table I. 
Colonization in all sites decreased with mupirocin 
use, but only when both nares and wounds were 
treated. 
The persistence of MRSA in the facility was due 
to several factors (Figure 3). The number of new 
patients admitted to the facility already colonized 
with MRSA did not decrease over the course of the 
year. Recurrences of colonization during mainte- 
nance mupirocin treatment decreased in the second 
5 months, but still continued to occur. New convert- 
ers did decrease in the second 5 months of the 
study, but the decrease was not significant. 
Transmission of MRSA in the Facility 
Among all patients in the facility, acquisition of 
MRSA of the same phage group that was carried by 
a roommate was noted in eight patients in the first 7 
months of the study, giving an incidence of trans- 
mission of 4%. This number is similar to that noted 
in the prior year when nine patients (3%) acquired 
MRSA of the same phage group noted in a room- 
mate. When mupirocin was used in both anterior 
nares and wounds in the next 5 months, no room- 
mate-to-roommate spread was documented. 
YRSA lnfectiins in the Facility 
Only 6 of 321 patients developed infection with 
MRSA over the course of the year, 3 in the first 7 
months and 3 in the next 5 months. Of these six 
patients, only three were known to be colonized 
with MRSA, two of these three had received treat- 
ment with mupirocin ointment for 2 weeks and 8 
weeks prior to infection, and the third patient had 
refused mupirocin treatment. There were three pa- 
tients with osteomyelitis, two with skin and soft 
tissue infections, one of whom was bacteremic, and 
one with a urinary tract infection. Five patients 
required hospitalization for intravenous vancomy- 
tin therapy; none died of their infection. 
This rate of development of infection (6 of 321 
patients, 1.9%) did not differ from that noted in the 
prior year of the study when 9 of 341 patients (2.6%) 
developed infection with MRSA while in the long- 
term-care facility. 
MRSA Contamination of the Environment 
At the start of the study, before mupirocin was 
used, 33 (9%) of 380 samples from the environment 
were positive for MRSA. This decreased to 5.3% (26 
of 488 sites sampled) after the first 7 months and 
0.6% (3 of 488 sites) by the end of the study, x2 = 
34.28, p = 0.0001. Floors by the patients’ beds gave 
the highest yield of cultures positive for MRSA in 
the first two samplings, 39% and 42% of all isolates, 
respectively. Bedside tables were next most com- 
monly positive for MRSA. Common resource areas 
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were infrequently found to be contaminated with 
MRSA, with one environmental sample positive in 
June 1990, four positive in January 1991, and one 
positive in June 1991. 
Development of Resistance to Mupirocin 
Of those patients treated with mupirocin, 7 of 65 
(10.8%) had 8 mupirocin-resistant MRSA strains 
isolated. Seven of these 8 strains showed low-level 
resistance to mupirocin (MIC 3.1 to 62.5 pg/mL) 
and 1 exhibited high-level mupirocin resistance 
(MIC greater than 5,000 pg/mL). Only one patient 
was colonized with a mupirocin-resistant strain at 
the time of admission to the facility, but it was later 
discovered that he had previously been treated with 
mupirocin at another facility. In five patients, the 
mupirocin-resistant strain was the same phage 
group as the prior colonizing strain, which was mu- 
pirocin-susceptible; two patients acquired a mupir- 
ocin-resistant strain that was a different phage 
group, and one isolate was not typed. Mupirocin- 
resistant organisms appeared in nares as well as 
wounds; four strains appeared in the first 7 months 
and four in the second 5 months of the study. All 
patients colonized with low-level mupirocin-resis- 
tant strains cleared their organism with continued 
mupirocin treatment. The patient with the high- 
level mupirocin-resistant MRSA isolate in his 
wound remained persistently colonized despite 
treatment with mupirocin. Neither he nor the other 
six patients developed infection with a mupirocin- 
resistant MRSA strain. 
In addition to the eight mupirocin-resistant 
MRSA isolates, four mupirocin-resistant MSSA 
strains were also isolated over the course of the year; 
all showed low-level resistance only. Only one mu- 
pirocin-resistant strain (a low-level resistant MSSA 
strain) was obtained from the environmental 
cultures. 
COMMENTS 
We have described the effects of long-term mu- 
pirocin use on both individual carriage of MRSA 
and overall colonization and infection rates within a 
long-term-care facility in which MRSA is endemic. 
We found that MRSA colonization of anterior nares 
alone or both anterior nares and wounds was quick- 
ly eradicated by mupirocin. Within a week, elimina- 
tion of MRSA had occurred in most patients who 
were treated. This immediate effect is similar to 
prior findings reported for S. aureus in our long- 
term-care facility [ 131, in hospitalized patients [ 111, 
and in patients undergoing long-term hemodialysis 
[19]. When mupirocin was used in health care work- 
ers with nares and/or hand colonization, similar ef- 
ficacy for eradication of S. aureus has been de- 
scribed [ 141. 
We found that monthly MRSA colonization rates 
in the long-term-care facility fell when mupirocin 
was applied to both nares and wounds of MRSA 
carriers. Similarly, environmental contamination 
with MRSA also decreased when wounds as well as 
nares were treated. However, we were unable to 
show a positive benefit of the use of mupirocin on 
MRSA infection rates. Most likely this is due to the 
small number of infections seen in our facility prior 
to the use of mupirocin [7]. On the other hand, in an 
outbreak situation with a high rate of MRSA infec- 
tions, decolonization measures employing mupiro- 
tin are more likely to be beneficial in decreasing the 
infection rate [11,20]. In addition, two groups have 
documented a decrease in S. aureus infections in 
hemodialysis patients after initiation of the use of 
mupirocin [21,22]. 
In outbreaks, mupirocin ointment, often com- 
bined with other measures, has been found to be 
efficacious when used for a short period of time 
[11,20,23]. However, in the endemic setting, long- 
term use of mupirocin may be necessary. In a prior 
study from our long-term-care facility, follow-up 
cultures at 1 and 2 months after 7 days of mupirocin 
therapy showed that 44% of patients had a recur- 
rence of S. aureus in their nares [13]. Most likely, 
the continuous introduction of new carriers of 
MRSA into the long-term-care setting obviates the 
benefit of short-term therapy with mupirocin. We 
sought to determine the minimum maintenance 
therapy required to prevent recurrences, and found 
that once-weekly application was not adequate to 
prevent breakthrough. In a different clinical situa- 
tion, that of a hemodialysis unit, Boelaert et al [19] 
reported that once-weekly mupirocin was adequate 
to prevent relapse. However, in the hemodialysis 
unit, cultures were only performed monthly and 
may have missed transient breakthroughs. 
We found that wounds, as well as nares, had to be 
treated to eradicate MRSA from wounds and to 
show an impact on overall colonization rates in the 
facility. This differs from findings in health care 
workers, in whom nasal application eliminated S. 
aureus from hands as well as naree (141. This proba- 
bly reflects transient colonization with lower num- 
bers of organisms on the hands of health care work- 
ers when compared with more heavily colonized 
wounds in patients. 
It is possible that the decrease in colonization was 
not directly related to the use of mupirocin, but was 
due to other factors. For example, the knowledge 
that a patient was colonized might change behavior 
on the part of the health care workers, inducing 
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them to change their practices. We think this is 
unlikely since we saw no changes in colonization 
rates in the first 7 months when the patients’ 
MRSA status was also known by the health care 
workers. Also, colonization rates in the first year, 
when the patients’ MRSA status was not shared 
with staff, were the same as that of the first 7 
months of the second year of the study. Only when 
mupirocin was used in both nares and wounds did 
MRSA colonization rates fall. 
No side effects of mupirocin treatment were 
found, as noted by others using the polyethylene 
glycol formulation [23-X] and the paraffin-based 
formulation [11,14]. It is important to note that 
none of the wounds we treated had a large surface 
area, as might be seen in a burn patient or in a 
patient with an extensive decubitus ulcer. In pa- 
tients with large wounds, absorption of polyethyl- 
ene glycol-containing agents, such as mupirocin, ni- 
trofurazone, or dextranomer beads, could occur and 
prove harmful [25]. 
It must be emphasized that the results we found 
may not apply to all long-term-care settings. 
MRSA has tended to be more prevalent in tertiary- 
care university hospitals and veterans facilities [3]. 
The physical attachment of the long-term-care fa- 
cility to the acute-care hospital, as well as the pres- 
ence of house staff to care for patients, differenti- 
ates our long-term-care facility from other 
community-based facilities. The fact that most of 
the patients were men may also make our findings 
not directly applicable to community-based long- 
term-care facilities serving predominantly women. 
When drugs are used over a long period of time in 
an attempt to decolonize carriers, a major concern is 
the selection of resistant organisms. This concern 
has come to fruition in prior studies aimed at eradi- 
cation of S. aureus with ciprofloxacin, rifampin, 
clindamycin, and trimethoprim-sulfamethoxazole 
[26-281. Strausbaugh et al [28] recently document- 
ed the ineffectiveness of a decolonization program 
in a Veterans Affairs long-term-care facility in 
which the emergence of MRSA strains resistant to 
rifampin and clindamycin was common. 
We documented both low-level and high-level re- 
sistance to mupirocin in isolates from patients in 
our facility. Resistance to mupirocin has now been 
reported in hospitals in England [29-341 and the 
United States [24,35]. Most resistance has been 
low-level, and perhaps may be of little clinical im- 
portance since the concentration of mupirocin is so 
high when applied as an ointment (20,000 ccg/mLl 
[lo]. In fact, our patients with low-level resistance 
all had MRSA clearance with continued mupirocin 
use, as have other S. aureus carriers described pre- 
viously [29,35]. This type of resistance is inducible 
in uitro with stepwise increases in mupirocin con- 
centration, and does not appear to be plasmid-me- 
diated or transferable. 
In contrast, high-level resistance is uncommon 
[29], is plasmid-mediated [31], and has been associ- 
ated with clinical failure to eradicate S. aureus 
[31,32]. In hospitals in England that have moni- 
tored susceptibility to mupirocin over several years, 
the percentage of resistant isolates of S. aureus is 
increasing [30,33,34]. This increase appears to be 
related to widespread use of the drug, especially in 
dermatology wards. We have also noted an increase 
in the number of institutions in our region using 
mupirocin liberally in an attempt to eradicate 
MRSA colonization. The concerns of those observ- 
ing the phenomenon of increasing mupirocin resis- 
tance are mirrored in our data, which show the 
emergence of resistance to mupirocin in association 
with chronic use in a long-term-care facility with a 
high endemic rate of MRSA colonization. 
Although overall MRSA colonization was de- 
creased in the facility, patients continued to be ad- 
mitted with MRSA and recurrences occurred in 
many patients receiving maintenance mupirocin 
treatment. Tracking all patients colonized with 
MRSA and following all patients undergoing main- 
tenance mupirocin therapy to ensure they had not 
had a recurrence required a half-time research as- 
sistant. The microbiologic resources required were 
considerably more than available for most long- 
term-care facilities. Taking into account the costs 
for labor and supplies required to monitor coloniza- 
tion, the lack of real benefit in decreasing infection 
rates, and the very significant drawback of selection 
of mupirocin-resistant organisms, we believe that 
mupirocin should not be used chronically in long- 
term-care facilities that have endemic MRSA. Re- 
serving mupirocin as one of several measures to stop 
an outbreak is a more appropriate use of this drug. 
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